TITLE: Securement for vascular access devices: Looking to the future

AUTHORS: Ullman, Amanda; Marsh, Nicole; Rickard, Claire

JOURNAL: British Journal of Nursing

Conflict of interest statement: Griffith University has received research grant funding to support the research of the authors, and educational speaker or consultancy fees that are unrelated to this project from intravenous dressing/securement manufacturers (3M, Adhezion, BBraun, Becton Dickinson and Company, Centurion Medical Products, Entrotech, Mayo Healthcare, Medtronic, ResQDevices). These funding bodies have had no role in the preparation of this manuscript.
Vascular access devices (VADs) form a necessary component of healthcare; up to 90% of patients admitted to hospital require insertion of a device to enable the administration of therapies, monitoring and diagnostics (Alexandrou et al., 2015, idata, 2015). The range of devices inserted is as diverse as the clinical conditions they are used for – peripheral intravenous catheters (PIVCs), midlines, peripherally inserted central catheters (PICCs), non-tunnelled and tunnelled central venous access devices (CVADs), totally implanted devices and many more specialty devices. These vary in shape and function, but across all types a basic characteristic prevails – a VAD is a foreign body, and something needs to stop it becoming dislodged either accidentally or intentionally.

Traditionally, clinicians focussed on VAD dressings, rather than thinking about securement (Ullman et al., 2015a). Gauze or plastic (polyurethane) dressing products are used to cover the insertion wound to prevent contact with the environment to prevent infection. However contemporary literature has brought to attention the common problem of accidental peripheral and central VAD dislodgement – for every 100 devices, 5-6% will be lost due to dislodgement (Wallis et al., 2014, Ullman et al., 2015c). Clinical trials and meta-analysis comparing gauze and polyurethane products in PIVC and CVAD (Ullman et al., 2015b, Marsh et al., 2015b) have not shown any difference in the prevention of device failure between the products. In addition a laboratory study demonstrated that polyurethane products added no extra security against dislodgement than when no dressing was applied at all (Simonova et al., 2012). Advances in securement technology and practice are urgently needed to reduce intentional and accidental dislodgement of VAD.

**Fundamentals to ensure VAD securement success**

The new Royal College of Nursing Standards for Infusion Therapy (Royal College of Nursing, 2016) incorporate the properties of stabilisation devices within their broader recommendations for VADs. However securement is not only about using new technology – to promote device security, fundamental VA management practices need also to be enhanced. Before investing in complex, expensive securement technologies, the basic principles of site preparation, skin health promotion, and regular site assessment should be optimised (Broadhurst et al., 2017). During patient assessment for VAD planning, clinicians should consider the best site for insertion to promote performance and longevity (Wallis et al., 2014), and this would include effective security. For example, a PIVC in the hand of a crawling toddler is at a high risk of dislodgment, a jugular CVC in a hirsute and diaphoretic adult male provides a high risk of dressing detachment and device dislodgement. Hair surrounding the intended VAD insertion site needs to be trimmed (Royal College of Nursing, 2016), and skin decontaminants (e.g., chlorhexidine gluconate) given adequate time to dry (Loveday et al., 2014), prior to any dressing and securement product being applied. The skin health of the surrounding the device must be maintained, and early signs of skin irritation or injury identified and effectively managed (Broadhurst et al., 2017). The dressing and securement products used must be regularly assessed to ensure they are kept clean, dry and intact (Loveday et al., 2014, Royal College of Nursing, 2016). However between 10 to 25% of hospital patients at any one time have dressings that do not fulfil these basic criteria of
being clean, dry and intact (Ullman et al., 2016a, New et al., 2014). With investment in these basic VAD management strategies, VAD securement technologies will be as effective as possible.

**The future of VA securement**

The last twenty years has seen great innovations in technology to promote VAD securement. Sutureless securement devices (SSD) were developed to replace or compliment sutures for CVADs including PICCs (Ullman et al., 2015a). However, while Yamamoto et al. (2002) demonstrated SSD significantly reduced PICC-related bloodstream infections (n=170; SSD 2%; suture 12%; p=0.032), there was no significant reduction in accidental dislodgement (SSD 12%; suture 14%; p>0.05). A recent trial by Rickard et al. (2016) examining a different type of SSD in non-tunnelled jugular CVADs in intensive care found no difference in accidental dislodgement between sutures (4%) and SSD (7%; p= not provided). Pilot studies in peripheral VAD found SSDs safe and feasible to apply (Marsh et al., 2015a, Reynolds et al., 2015, Edwards et al., 2014), with a large, efficacy study soon to be published (Rickard et al., 2015).

Another potential product to assist with VAD security is tissue adhesive, which is a medical grade ‘superglue’ (cyanoacrylate) used previously to close skin lacerations and soft tissue wounds as an alternative to sutures or staples (Singer and Thode, 2004, Aukerman et al., 2005). Tissue adhesive used in small amounts (only 1-2 drops at the insertion site and under the hub) has been successfully applied to prevent failure for PIVC (Bugden et al., 2016, Marsh et al., 2015a), peripheral arterial catheters (Reynolds et al., 2015), and non-tunnelled CVAD (Rickard et al., 2016). Tissue adhesive also has haemostatic properties that reduce post insertion bleeding and haematomas; which is advantageous for CVADs immediately post-insertion. Tissue adhesive’s bactericidal properties include inhibition of all Gram-positive organisms (predominant cause of VAD infections), including *Staphylococcus Aureus* (Wilkinson et al., 2008, Simonova et al., 2012). Like SSDs, tissue adhesive is used in conjunction with polyurethane dressings.

An emerging technology is the use of subcutaneously anchored security devices. The devices are placed alongside the VAD, and incorporate a small blunt anchor which is positioned under the skin into the subcutaneous tissue during catheter placement (Elen Hughes, 2014). They can remain in place for the entire VAD dwell. Observational, clinical evaluations examining their use in PICCs have found them acceptable to patients, and potentially effective at reducing dislodgement and migration (Elen Hughes, 2014, Zerla et al., 2017, Egan et al., 2013), however concerns remain regarding patient discomfort and risk of PICC-related infection (Elen Hughes, 2014, Zerla et al., 2017). High quality research regarding this technology is necessary, with a randomised trial from Belgium expected to be published in 2017.

Integrated VAD securement- dressing technologies represent an alternative to the application of two separate dressing and securement products (e.g. suture and polyurethane dressings). Newer generation integrated products include reinforced, fabric borders surrounding
polyurethane, as well as additional adhesive components that holds VAD from beneath, as well as above (Ullman et al., 2015a). Currently being evaluated in clinical trials in CVADs and PICCs (Ullman et al., 2016b), if shown to be effective at promoting security the merger of these products has implications for associated costs, and labour (Ullman et al., 2015a).

Also emerging in clinical practice and literature is the partial tunnelling of traditionally un-tunelled CVADs, including PICCs, to promote security and reduce bleeding and infection (Elli et al., 2017). Termed the “extended subcutaneous route” technique, it allows the creation of a subcutaneous tunnel of less than 5 cm, without skin incision and extended manipulation (Elli et al., 2017). To date the technique has been demonstrated to be feasible, for example with femoral CVADs tunnelled a short distance down the thigh, or jugular CVADs tunnelled to exit on the chest, however little data regarding its effectiveness to improve security are available (Elli et al., 2017).

In addition to new, potentially exciting technologies, traditional low-cost products that have not yet been rigorously evaluated should not be ruled out, for example backboards/splints and elasticised net tubing. Non-sterile paper tape, probably the most common securement that nurses apply (Alexandrou et al., 2015), yet no targeted studies exist to advise optimal amounts, placement, or whether other forms of non-sterile or sterile tape would be more effective.

**Complex situations requiring complex solutions**

Patient populations requiring VADs are varied and their histories are frequently complex. Underlying comorbidities, poor vasculature and rapidly fluctuating clinical conditions mean that VA requirements are rarely static. ‘One size fits all’ solutions for security and dressing are impractical and ineffective (Broadhurst et al., 2017). This is especially evident when considering skin injuries surrounding VA, such as skin tears and allergies. A recent point prevalence study in Australia found 10% of paediatric CVAD sites were associated with some form of skin injury (Ullman et al., 2016a), and this may be echoed in other populations and devices. However international and local clinical practice guidelines rarely acknowledge or provide recommendations for how to effectively dress and secure VAD within complex situations (Broadhurst et al., 2017).

Re-establishing the fundamentals, re-considering old, and implementing new technologies will likely result in improved VAD security, and outcomes for patients. With the range of innovations in development, it will be a significant advantage to have an assortment of effective VAD securement products available for different, sometimes difficult, clinical situations. However clinical decision-making regarding different VAD security products must be supported by high quality evidence (randomised trials and systematic reviews of randomised trials), to ensure effective treatment and judicious use of healthcare resources.
References


